Expert Interview
A Second Opinion: Looking at the potential of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon, recently acquired by Novo Nordisk.
Ticker(s): NVOInstitution: Centracare
- Board Certified Endocrinologist fellowship trained at University of California San Francisco.
- Manages ~400 patients annually for weight loss and obesity.
- Practicing in endocrinology for over 20 years.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
